Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Immuneering Corp Cl A (IMRX)

Immuneering Corp Cl A (IMRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 63,342
  • Shares Outstanding, K 31,050
  • Annual Sales, $ 0 K
  • Annual Income, $ -53,470 K
  • EBIT $ -62 M
  • EBITDA $ -62 M
  • 60-Month Beta -0.40
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.92

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.47
  • Number of Estimates 4
  • High Estimate -0.30
  • Low Estimate -0.62
  • Prior Year -0.52
  • Growth Rate Est. (year over year) +9.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.68 +21.25%
on 11/13/24
2.21 -7.69%
on 10/23/24
-0.20 (-8.93%)
since 10/18/24
3-Month
1.01 +101.98%
on 08/23/24
3.83 -46.74%
on 09/16/24
+0.97 (+90.65%)
since 08/20/24
52-Week
1.00 +104.00%
on 08/16/24
8.89 -77.05%
on 12/04/23
-3.54 (-63.44%)
since 11/20/23

Most Recent Stories

More News
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

IMRX : 2.04 (unch)
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer

IMRX : 2.04 (unch)
FDA Oncology Approvals Accelerate as Global Cancer Rates Set to Climb 77%

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Although death rates for some cancers are declining, the world is facing a sharp increase in cancer...

ONCY : 0.9985 (-5.80%)
ZNTL : 3.13 (+4.68%)
TIL : 23.36 (-10.84%)
IMRX : 2.04 (unch)
ZLAB : 26.23 (+0.31%)
ONC.TO : 1.40 (-5.41%)
Pancreatic Cancer Battle Intensifies with Biotech Sector's Advanced Treatments

USA News Group – A new study is bringing hope in the fight against one of the deadliest cancers, revealing a blood test that can detect early-stage pancreatic cancer with 97% accuracy. This breakthrough...

ONCY : 0.9985 (-5.80%)
ONC.TO : 1.40 (-5.41%)
RHHBY : 35.1300 (-0.79%)
MRUS : 42.93 (-1.29%)
MGNX : 3.28 (-5.75%)
IMRX : 2.04 (unch)
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth

EQNX::TICKER_START (ONASDAQ:ONCY),(TSX:ONC),(NASDAQ:BLRX),(NASDAQ:IMRX),(NASDAQ:CADL) EQNX::TICKER_END

ONCY : 0.9985 (-5.80%)
ONC.TO : 1.40 (-5.41%)
BLRX : 0.5452 (+1.64%)
IMRX : 2.04 (unch)
CADL : 3.98 (-0.25%)
Why Shares of Immuneering Jumped This Week

Immuneering is ready to share information regarding its lead therapy.

IMRX : 2.04 (unch)
Pyramid Biosciences Names Biren Amin as Chief Financial and Strategy Officer

Pyramid Biosciences, Inc., a Boston-based, clinical-stage, biotechnology company focused on developing new and highly differentiated precision therapies for cancer, today announced the expansion of its...

IMRX : 2.04 (unch)
Immuneering Announces Participation in William Blair Biotech Focus Conference 2022

CAMBRIDGE, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational...

IMRX : 2.04 (unch)
Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104

IMM-1-104 strongly inhibits tumor growth in an animal model of KRAS-G12V mutant pancreatic cancer Preclinical data package now includes animal studies...

IMRX : 2.04 (unch)
Immuneering Announces Participation in Upcoming Investor Conferences

CAMBRIDGE, Mass., May 20, 2022 (GLOBE NEWSWIRE) --  Immuneering Corporation (NASDAQ: IMRX), a biopharmaceutical company using translational...

IMRX : 2.04 (unch)

Business Summary

Immuneering Corporation is a biopharmaceutical company advancing a pipeline of oncology and neuroscience product candidates. The company's product candidate includes IMM-1-104. Immuneering Corporation is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 2.20
2nd Resistance Point 2.15
1st Resistance Point 2.09
Last Price 2.04
1st Support Level 1.98
2nd Support Level 1.93
3rd Support Level 1.87

See More

52-Week High 8.89
Fibonacci 61.8% 5.88
Fibonacci 50% 4.95
Fibonacci 38.2% 4.01
Last Price 2.04
52-Week Low 1.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar